Perpetua Medical strengthens Spirotronic with new leadership, a lower cost base and increased commercial focus

Perpetua Medical AB (publ) ("Perpetua Medical" or the "Company") has implemented a series of measures at Spirotronic to improve profitability, strengthen its commercial focus and create better conditions for profitable growth. These measures include the appointment of a new Managing Director and a reduction in the cost base. The measures follow Spirotronic's financial performance in 2026, which has fallen short of Perpetua Medical's expectations.

The changes are intended to establish a more cost-efficient and commercially driven organisation, with a stronger emphasis on sales and business development. Perpetua Medical continues to see significant potential in Spirotronic's specialist services, products and technology, particularly through opportunities to secure so-called design wins, whereby Spirotronic's technology and critical components are incorporated into medical devices with significant production volume potential.

Anders Hedlund, CEO of Perpetua Medical, comments:

"Spirotronic's performance in 2026 has fallen short of our expectations, and we have therefore taken action. Our decentralised ownership model is built on a high degree of local responsibility, but also on our commitment as an active owner to intervene when performance deviates from plan. The changes being implemented will establish a lower cost base, sharpen the commercial focus and put Spirotronic in a stronger position to realise the significant potential we continue to see in its products, technology and specialist expertise."

The cost reductions implemented are expected to have their full effect from the first quarter of 2027.

The information was submitted for publication, through the agency of the contact person set out below, on November 24, 2026 at 8:30 AM CEST.

For further information

Anders Hedlund, CEO

Tel: +46 18 71 13 32

Email: anders.hedlund@perpetuamedical.se

Certified Adviser

Perpetua Medical's Certified Adviser is Mangold Fondkommission AB, which can be contacted by telephone at +46 8 5030 15 50 or by email at ca@mangold.se.

About Perpetua Medical AB (publ)

Perpetua Medical acquires profitable, product-oriented companies in the healthcare sector. The Company believes that a decentralised ownership model, in which operations and decision-making are entrusted to independent subsidiaries, provides the best foundation for value creation. The name Perpetua (Latin for “everlasting”) Medical reflects the Company's strategy of acquiring healthcare businesses with the intention of owning them indefinitely, without a predetermined exit horizon.

The Company's shares (ticker: PERP B) are traded on Nasdaq First North Growth Market in Stockholm.

For more information, please visit http://perpetuamedical.se/.